Lacolle Peters

Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial

Alex F. Herrera, Lu Chen, Yago Nieto et al. · The Lancet Haematology · 2022 · 40 citations

Medicine, Hematology, Oncology +15

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Matthew Mei, Lu Chen, James Godfrey et al. · Blood · 2023 · 40 citations · Full text

Medicine, Oncology, Pharmacology +16

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Alex F. Herrera, Lu Chen, Leslie Popplewell et al. · Blood · 2019 · 23 citations

Medicine, Hematology, Oncology +17

Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma

Alex F. Herrera, Lu Chen, Yago Nieto et al. · Blood · 2020 · 20 citations

Medicine, Hematology, Oncology +16

Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas

Alex F. Herrera, Jasmine Zain, Kerry J. Savage et al. · Blood · 2021 · 20 citations

Medicine, Hematology, Oncology +13